Related Experiment Videos
Therapy of acute hepatitis C
Alfredo Alberti1, Silvia Boccato, Alessandro Vario
1Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy. alfredo.alberti@unipd.it
Hepatology (Baltimore, Md.)
|October 31, 2002
Summary
Treating acute hepatitis C infection with interferon can reduce the progression to chronic hepatitis C virus (HCV) infection by 30-40%. While generally well-tolerated, optimal treatment strategies require further investigation.
Area of Science:
- Hepatology
- Virology
- Infectious Diseases
Background:
- Acute hepatitis C frequently progresses to chronic infection.
- Early treatment is a strategy to prevent chronicity.
- Existing studies on acute hepatitis C treatment are limited in scope and design.
Purpose of the Study:
- To review the current evidence for treating acute hepatitis C.
- To assess the efficacy and tolerability of interferon-based therapies.
- To identify gaps in knowledge regarding optimal treatment regimens.
Main Methods:
- Review of published literature on acute hepatitis C treatment.
- Analysis of meta-analyses evaluating interferon monotherapy.
- Assessment of study heterogeneity regarding patient characteristics, treatment protocols, and outcome measures.
Main Results:
- Interferon monotherapy in the acute phase significantly reduces the evolution to chronic hepatitis C (30-40%).
- Interferon treatment is well-tolerated in acute hepatitis C patients, with side effects comparable to chronic cases.
- Limited data exist on combination therapies (interferon/ribavirin, peginterferon).
Conclusions:
- Current data support treating acute hepatitis C with interferon.
- Further research is needed to determine optimal patient selection, timing, and regimens (including peginterferons).
- Future studies should address whether immediate treatment or delayed therapy (2-4 months) is superior, considering spontaneous recovery rates.